ZA864769B - Process and composition for treatment of cancer and non-malignant tumors - Google Patents

Process and composition for treatment of cancer and non-malignant tumors

Info

Publication number
ZA864769B
ZA864769B ZA864769A ZA864769A ZA864769B ZA 864769 B ZA864769 B ZA 864769B ZA 864769 A ZA864769 A ZA 864769A ZA 864769 A ZA864769 A ZA 864769A ZA 864769 B ZA864769 B ZA 864769B
Authority
ZA
South Africa
Prior art keywords
cancer
treatment
malignant tumors
compositions
composition
Prior art date
Application number
ZA864769A
Other languages
English (en)
Inventor
Gary R Landucci
Toni N Mariani
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of ZA864769B publication Critical patent/ZA864769B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ZA864769A 1985-06-28 1986-06-26 Process and composition for treatment of cancer and non-malignant tumors ZA864769B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75009185A 1985-06-28 1985-06-28

Publications (1)

Publication Number Publication Date
ZA864769B true ZA864769B (en) 1987-02-25

Family

ID=25016458

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA864769A ZA864769B (en) 1985-06-28 1986-06-26 Process and composition for treatment of cancer and non-malignant tumors

Country Status (13)

Country Link
EP (1) EP0227809B1 (de)
JP (1) JPS62503144A (de)
CN (1) CN86104913A (de)
AT (1) ATE80802T1 (de)
AU (1) AU597265B2 (de)
CA (1) CA1341303C (de)
DE (1) DE3686811D1 (de)
DK (1) DK107787D0 (de)
ES (1) ES8800981A1 (de)
HU (1) HUT43495A (de)
IL (1) IL79260A (de)
WO (1) WO1987000054A1 (de)
ZA (1) ZA864769B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
AU3601299A (en) * 1998-04-09 1999-11-01 I.D.M. Immuno-Designed Molecules Use of monocytes derived cells and antibodies in a synergic way for optimal induction of immunotherapeutic efficiency
US6868665B2 (en) 2001-12-21 2005-03-22 General Electric Company Methods and apparatus for operating gas turbine engines
US7200538B2 (en) 2003-01-15 2007-04-03 General Electric Company Methods and apparatus for modeling gas turbine engines

Also Published As

Publication number Publication date
IL79260A0 (en) 1986-09-30
EP0227809B1 (de) 1992-09-23
CN86104913A (zh) 1987-05-27
ATE80802T1 (de) 1992-10-15
HUT43495A (en) 1987-11-30
IL79260A (en) 1990-11-29
ES8800981A1 (es) 1987-12-01
DK107787A (da) 1987-03-02
AU597265B2 (en) 1990-05-31
JPS62503144A (ja) 1987-12-17
DK107787D0 (da) 1987-03-02
EP0227809A4 (de) 1987-10-19
CA1341303C (en) 2001-10-09
DE3686811D1 (de) 1992-10-29
AU6125486A (en) 1987-01-30
ES556684A0 (es) 1987-12-01
EP0227809A1 (de) 1987-07-08
WO1987000054A1 (en) 1987-01-15

Similar Documents

Publication Publication Date Title
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
AU561016B2 (en) N-glycosylated carboxamide derivatives
HUT63063A (en) Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
GR3026219T3 (en) Mouse monoclonal antibodies
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
IL92037A0 (en) Novel family of high affinity,modified antibodies for cancer treatment
ZA864769B (en) Process and composition for treatment of cancer and non-malignant tumors
FR2471785B1 (de)
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
HUT51594A (en) Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody
AU562964B2 (en) Platinum-diamine complexes, a process for the preparation thereof, a process for the preparation of a medical composition using a such platinum-diamine complex for the treatment of cancer, as well as the thus shaped composition
IL76289A (en) Tumor therapeutic agent and a process for its preparation
PT73950A (fr) Procede de preparation de composes de dichloredietilaminopheni-lalanine d'action antitumureuse
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
ES8304582A1 (es) Procedimiento para preparar compuestos de estano.
ES2013046A6 (es) Procedimiento para preparar una proteina marcada con un radionuclido metalico.